Chronic Obstructive Pulmonary Disease (COPD) - Executive Market Summary 2011Timely Data Resources, Inc.June 3, 2011 14 Pages - SKU: TDR6403522 |
| The Chronic Obstructive Pulmonary Disease (COPD) Executive Market Summary 2011 provides an overview of the disease and related conditions, with prevalence and mortality numbers and percentages for major countries worldwide, information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the COPD market, as well as sales of leading drugs and therapies are provided.
Please note, this file is delivered as a Word file. |
Additional Information
Executive Market Summaries were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Executive Market Summary provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.
Related Markets
Respiratory/Pulmonary Reports
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors
- Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
- Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012

